論文・技術情報追加のお知らせ

1. Safety Assessment of Glucagon-Like Peptide 1 Receptor Agonists Based on the FAERS Database: Focus on Tumorigenic Risk in Subpopulations.

GLP-1受容体作動薬のサブグループ別腫瘍発生リスクを解析。

対象DB：FAERS

2. Cancer risk associated with DPP4 inhibitors in type 2 diabetes: A pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS).

2型糖尿病におけるDPP-4阻害薬とがんリスクの関連を解析。

対象DB：FAERS

3. Persistent rise in device-related errors for CGRP monoclonal antibodies: impact of the COVID-19 pandemic and post-pandemic implications.

コロナ禍におけるCGRP抗体薬のデバイス関連エラー増加を調査。

対象DB：FAERS

4. EGFR-targeted agents and paronychia: a FAERS-based real-world pharmacovigilance analysis.

EGFR標的薬による爪囲炎リスクをFAERSデータに基づき解析。

対象DB：FAERS

5. Real-world safety of satralizumab in neuromyelitis optica spectrum disorder: a FAERS-based risk stratification study.

サトラリズマブの副作用をFAERSで解析しリスク層別化。

対象DB：FAERS

6. Signal detection of drug-induced esophageal ulcer across 20 years of real-world study: Focus on 49 high-risk medicines.

薬剤性食道潰瘍のリスクシグナルを20年間のFAERSデータで解析。

対象DB：FAERS

7. Evaluation of the real-world safety of eptifibatide in the treatment of ARDS: results of a disproportionality analysis of FAERS data.

ARDS治療におけるエプチフィバチドの安全性を不均衡解析。

対象DB：FAERS

8. MSAT: a FAERS-informed heterogeneous graph neural network for pharmacovigilance prediction of Chinese materia medica-associated adverse drug reactions.

グラフニューラルネットワークを用い漢方薬の副作用を予測。

対象DB：FAERS

9. Post-marketing safety of CGRP monoclonal antibodies and gepants: A systematic review of spontaneous reporting system data.

CGRP抗体薬およびゲパント系の市販後安全性を系統的レビュー。

対象DB：EudraVigilance,FAERS,VigiBase

10. Ocular adverse events associated with aflibercept and faricimab: a population-based pharmacovigilance study.

アフリベルセプトとファリシマブの眼科的副作用を比較解析。

対象DB：FAERS

11. Risk factors for drug-related ischemic stroke: an analysis of the FDA adverse event reporting system (FAERS).

薬剤性虚血性脳卒中のリスク因子をFAERSデータから特定。

対象DB：FAERS

12. Bile acids as candidate therapies for multiple sclerosis: inverse signal analysis using the FDA adverse event reporting system and preclinical validation.

胆汁酸の多発性硬化症への治療効果をFAERSの逆シグナルで解析。

対象DB：FAERS

13. Quantifying new threats to health and biomedical literature integrity from rapidly scaled publications and problematic research.

出版規模拡大に伴う健康・生物医学文献の完全性への脅威を評価。

対象DB：FAERS

14. Estimation of Respiratory Syncytial Virus-attributable hospitalizations among older adults in Japan between 2015 and 2018: An administrative health claims database analysis.

日本の高齢者におけるRSウイルス関連入院数をレセプトで推計。

対象DB：DPC,MDV

15. Risk factors for postextubation pneumonia using diagnosis procedure combination and claims data in Japan.

抜管後肺炎のリスク因子をDPCおよびレセプトデータで解析。

対象DB：DPC

16. Tranexamic acid reduces transfusion requirements after pelvic osteotomy: a nationwide propensity score-matched analysis.

骨盤截骨術後のトラネキサム酸による輸血減少効果を全国調査。

対象DB：DPC

17. Retrospective epidemiological study on cervical fracture dislocation in adolescents using the Diagnosis Procedure Combination database in Japan.

日本のDPCデータを用い、若年者の頸椎脱臼骨折を疫学調査。

対象DB：DPC

18. Shifting surgical strategies for osteonecrosis of the femoral head: evidence from a nationwide Japanese database.

日本の全国データから大腿骨頭壊死症の手術戦略の変遷を調査。

対象DB：DPC

19. Granulocyte and monocyte adsorption therapy in sepsis: a propensity score-matched analysis.

敗血症への顆粒球・単球吸着療法の効果をPSマッチングで解析。

対象DB：JMDC

20. Association between modifiable lifestyle factors and the incidences of sudden sensorineural hearing loss and Meniere's disease: A population-based nested case-control study.

修正可能な生活習慣と突発性難聴の発症リスクの関連を解析。

対象DB：NDB

21. Real-World Treatment Patterns of Elranatamab in Patients with Multiple Myeloma in Japan: The EVEREST Study.

日本の多発性骨髄腫患者におけるエルラナタマブの治療実態。

対象DB：MDV

22. Retrospective real-world database study to examine the prevalence and incidence of cardiovascular diseases and medication prescription in Japanese patients with type 2 diabetes.

日本のレセプトデータを用い、心血管疾患の有病率・発症率を調査。

対象DB：MDV

23. Evaluation of Real-world treatment patterns in Japanese patients with cGVHD: A retrospective claims database study.

日本の慢性GVHD患者におけるリアルワールドの治療パターン。

対象DB：MDV

24. Safety evaluation of afatinib in patients with a history of interstitial lung disease using data from an administrative claims database in Japan.

間質性肺疾患既往のある患者におけるアファチニブの安全性を評価。

対象DB：MDV

25. Defining recurrent urinary tract infections and quantifying bladder cancer risk in primary care in England: a nationwide case-control study.

英国のプライマリケアデータを用い、膀胱がんリスクを定量化。

対象DB：CPRD

26. Cardiometabolic prediction models for young people with psychosis spectrum disorders in the UK (PsyMetRiC 2.0): a retrospective, multicohort clinical prediction model study.

英国の精神病スペクトラム若年者向け心血管代謝予測モデル構築。

対象DB：CPRD

27. Time and patient journey to axial spondyloarthritis diagnosis: a retrospective study in French primary care.

フランスのデータから軸性脊椎関節炎診断までの経過を調査。

対象DB：THIN

28. Impacts of cost-sharing rate increment on the expenditure of outpatient care among older adults: quasi-experimental study of cost-sharing reform in Japan.

負担増が高齢者の外来医療費に与える影響を不連続回帰で解析。

対象DB：DeSC